Similar articles

• Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment.

  Clement-Cormier Y. Clement-Cormier Y. Adv Biochem Psychopharmacol. 1980;24:103-11. Adv Biochem Psychopharmacol. 1980. PMID: 6105768 No abstract available.
• Neuroleptic/dopamine receptors: elevation and reversal.

  List S, Seeman P. List S, et al. Adv Biochem Psychopharmacol. 1980;24:95-101. Adv Biochem Psychopharmacol. 1980. PMID: 6105811 Review. No abstract available.
• Dopamine receptor binding of a novel dibenzodioxazocine derivative, EGYT-2509.

  Gyüre K, Szentendrei T, Kanyicska B, Fekete MI, Rónai AZ. Gyüre K, et al. Pol J Pharmacol Pharm. 1985 May-Jun;37(3):253-61. Pol J Pharmacol Pharm. 1985. PMID: 2866498
• Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.

  Gnegy M, Uzunov P, Costa E. Gnegy M, et al. J Pharmacol Exp Ther. 1977 Sep;202(3):558-64. J Pharmacol Exp Ther. 1977. PMID: 19618 No abstract available.
• Central nervous system dopamine receptors.

  Creese I. Creese I. Adv Biochem Psychopharmacol. 1980;21:235-42. Adv Biochem Psychopharmacol. 1980. PMID: 6103649 Review. No abstract available.